GW Pharmaceuticals announced the successful closing of the European Mutual Recognition Procedure in France for Sativex oromucosal spray in the treatment of spasticity due to Multiple Sclerosis and a resulting recommendation for approval by the French authorities. The next step in the regulatory process is to work with the French National Agency of Medicine and Health Products Safety to finalize any country-specific requirements. Following completion of this next step, it is then expected that France will issue a national marketing authorisation. Launch timing in France is dependent on completion of subsequent national pricing and reimbursement procedures. Sativex will be commercialized in France by GW's European partner, Almirall S.A.